ENBREL for Psoriatic Arthritis

Psoriatic arthritis is an inflammatory autoimmune disorder that affects the skin and both proximal and distal joints1

General Statistics

  • Up to 30% of people diagnosed with plaque psoriasis actually have psoriatic arthritis.2-5
  • People of all ages can develop psoriatic arthritis, but the peak incidence is between 30 and 50 years of age.5
  • It has been observed that 48%-57% of patients experienced joint damage by the time they were diagnosed with psoriatic arthritis.6,7
  • In up to 70% of psoriatic arthritis patients, skin symptoms precede joint symptoms.1,8
  • In psoriatic arthritis, joint symptoms generally present 10 years after skin symptoms, but both may present simultaneously.1,9

ENBREL can provide significant improvement in psoriatic arthritis symptoms10

ENBREL is indicated for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in patients with psoriatic arthritis. ENBREL can be used in combination with methotrexate in patients who do not respond adequately to methotrexate alone.

Learn More about the Efficacy of ENBREL in Psoriatic Arthritis

Important Safety Information Prescribing Information Medication Guide
Indications
 
Moderate to Severe Rheumatoid Arthritis Supportive Data Psoriatic Arthritis Supportive Data
Safety Information ISI
See how Phil Mickelson stayed "on course" after a diagnosis of psoriatic arthritis just after the 2010 U.S. Open. See Phil's story

Information for Primary Care Physicians

Is your patient showing signs of rheumatoid arthritis or psoriatic arthritis?

View a list of common symptoms
ENBREL has helped Jack manage his psoriatic arthritis symptoms.
Jack S., ENBREL PsA patient since 2004
Prescribing Information Medication Guide
 
 
Close
You are leaving Enbrel.com/RheumPro
Please know that Amgen and Pfizer do not endorse and are not responsible for the content included on the site you are about to enter. Click the "Continue" button to proceed.
Continue Cancel

To return to ENBREL.com, click "Cancel" or close this window.

Privacy Policy  Terms of Use
This site is intended for US Audiences only.
©2011 Amgen, Inc., Thousand Oaks, CA 91320 and Pfizer Inc
Close
E-mail this page to a colleague
Please correct the fields marked in red
Send
This content is for US health care professionals only. Amgen and Pfizer will not use your e-mail address or your colleague's e-mail address for any other purpose. To learn more about our use of your information and your rights, please consult our Privacy Policy.
Close

Send another e-mail
Return to enbrel.com/RheumPro

Close
Notice

The following information is intended for use only by residents of the United States. Countries outside of the United States may have regulatory requirements or medical practices that are different than those in the United States and may require reference to different or additional information. Therefore, this information may not be appropriate outside of the United States.

If you are a resident of the United States or one of its territories, or a health care professional practicing your profession in the United States or one of its territories, please click below.

Continue

If you are a resident of a country other than the United States, please visit the Pfizer website and the Amgen website to find information about our offices around the globe.
Close
Close
Disease activity vs. structural progression in RA